Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 11, 2011, under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 590,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,197.5 pence per share; lowest price paid was 1,182 pence per share.
- Treasury Holdings (Settled): 488,189,284 shares (8.61% of total issued share capital).
- Treasury Holdings (Including Unsettled): 490,254,284 shares (9.46% of total voting rights).
- Shares in Issue: 5,182,848,191 shares (excluding treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 590,000 shares on March 11, 2011. Consequently, the percentage of total voting rights held in Treasury increased to 9.46% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The stated intention is to hold the repurchased shares in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (488,189,284 settled) against the company's latest capitalization table.
- Confirm the total issued share capital excluding treasury shares (5,182,848,191) for disclosure threshold calculations under FSA rules.
- Check the status of the 2,065,000 shares purchased but not yet settled to confirm final treasury ownership percentages.